We sought to evaluate whether the most common clinical conditions leading to recurrent SPTB were associated with differences in delivery gestational age (GA). STUDY DESIGN: This is a secondary analysis of four prospective, multicenter studies that enrolled women at high risk for SPTB 15-36 weeks; study #1¼observational, studies #2 & #3 ¼ RCTs with negative findings (intervention did not impact SPTB rate or neonatal outcomes); study #4 ¼ RCT of MgSO4 vs. placebo showing reduction in cerebral palsy at age 2 with MgSO4 treatment. We included women with singleton, non-anomalous pregnancies with 1 prior SPTB <37 weeks who had a recurrent PTB <37 weeks. Each woman was assessed for the presence of 1 possible underlying recurrent SPTB etiologies using uniform definitions and clinical data available antenatally: (a) intra-amniotic infection, (b) placental abruption, (c) pre-eclampsia / IUGR, and (d) PPROM (Table 1) . Maternal characteristics and delivery GA were compared for each phenotype. Data were analyzed with chi-square, t-test, Cox regression, and KaplanMeier survival analyses. RESULTS: 1,205 women met inclusion criteria; the mean delivery GA was 31.4 +/-4.1 weeks. 531 (44%) had 1 phenotype and 185 (15%) had 2 phenotypes. The most common phenotype was PPROM, followed by intra-amniotic infection and placental abruption. Women with each of these phenotypes delivered earlier than those without each phenotype (Table 1) . Black women were more likely to have PPROM (53.5% vs. 46.5%, p¼0.003) compared to women of other races. Overall, 37% used 17P; women who received 17P delivered later than those who did not receive 17P (32.8 vs. 30.5 weeks), p<0.001. In Cox regression models adjusted for black race, 17P, and smoking, intra-amniotic infection (Hazard Ratio 2.34, 95% CI 1.49-3.66), placental abruption (Hazard Ratio 1.78, 95% CI 1.21-2.59), and PPROM (Hazard Ratio 1.40, 95% CI 1.15-1.72) were associated with an earlier delivery GA, whereas pre-eclampsia/IUGR was associated with a later delivery GA (Hazard Ratio 0.76, 95% CI 0.60-0.97). In Kaplan-Meier survival analyses adjusting for black race, 17P, and smoking, each additional phenotype was associated with earlier GA at delivery, log-rank p<0.001 (Figure 1) . CONCLUSION: Women with a history of SPTB who subsequently have a recurrent SPTB and are clinically identified to have evidence of intra-amniotic infection, abruption, or PPROM deliver earlier than those without each of these phenotypes.
554 Melatonin for prevention of placental malperfusion and fetal compromise associated with intrauterine inflammation-induced oxidative stress OBJECTIVE: Oxidative stress induces vasoconstriction, hypercoagulation and pathologic vascular remodeling. We hypothesized that maternally-administered melatonin may reduce oxidative stress, hypercoagulability and structural injury in placenta, and prevent fetal sequelae in a mouse model of intrauterine inflammation(IUI)-induced oxidative stress. STUDY DESIGN: CD1 pregnant dams were randomized to intrauterine injections of either lipopolysaccharide (LPS; a model of IUI) or phosphate-buffered saline (PBS) at E17 as follows: (1) control (C); (2) Melatonin (M); (3) LPS (L); (4) LPS with Melatonin group (LM). Doppler ultrasonography was utilized to obtain fetal and maternal hemodynamic measurements in utero. Proinflammatory mediators (NFkB, TNFa, and IL1b), oxidative stress markers (4-HNE) and antioxidant mediators (Nrf2, HO1) were analyzed in the placenta by real-time RT-qPCR and western blots. Confirmatory histochemistry (PTAH, H&E, Nissl staining) and immunohistochemical analyses (Vimentin & CD31, a vascular endothelial cell marker; and Iba1, a marker of microglial activation) were performed. RESULTS: The systolic/diastolic (S/D) ratio, resistance index (RI) and pulsatility index (PI) in uterine artery (UtA) and umbilical artery (UA) were significantly increased in L compared to C, M, or ML groups. The rate of early diastolic notch in the UtA and the rate of absent end-diastolic flow (AEDF) in UA were significantly higher in L than C, M, or ML. Tei indices were significantly increased in L compared to C, M, or ML. The rate of abnormal Tei indices (>0.44) was significantly higher in L compared to C, M, or ML. The expression of SIRT1, Nrf2 and HO1 in the placenta were significantly decreased in L comparing to C or ML. The expression of NFkB, TNFa, and IL1b were significantly increased in L comparing to C, and ML. 4-HNE was increased in L comparing to C, M and ML. The area of vimentin in the placenta was decreased in L than C or M. PTAH staining in the placenta showed increased deposit of fibrin in L comparing to C, M, or ML. Iba1 expression was increased in fetal brains in L compared to C, M, and ML. CONCLUSION: Maternal pretreatment with melatonin appears to modulate maternal placental malperfusion, fetal cardiovascular compromise and fetal neuroinflammation induced by intrauterine oxidative stress. Current results suggest that melatonin could serve as a new preventive and/or therapeutic agent to prevent fetal injury from IUI-induced oxidative stress.
